Topic: off-label marketing
More than three years into a French investigation of its anti-epilepsy med Depakine, Sanofi will now face charges that could end up in a courtroom.
A year after facing insider trading claims, Sun Pharma now must fight charges it fired two former employees for refusing to market its meds off-label.
Jurors smacked J&J with a massive $8 billion verdict in the case of a young man who developed breasts while taking its antipsychotic drug Risperdal.
Nine years after the whistle first blew, Abbott and AbbVie have settled claims that they paid kickbacks to pump up TriCor sales.
Texas spanked AstraZeneca as a repeat offender in announcing a pair of off-label marketing settlements.
A former Biogen sales manager has sued the company claiming she was let go after she filed a corporate integrity complaint.
The feds charged five doctors over accepting Insys' bribes and said they've secured cooperation from two former employees.
Aegerion admitted in court that it touted its cholesterol med Juxtapid for patients with a disease it wasn't approved to treat.
A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."
Federal agents arrested Insys founder John Kapoor and charged him with racketeering and other felonies.